Neck

Atopic Dermatitis Treatment Global Market Report 2022: Increasing Adoption of Biological Therapies Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

Due to such factors, the atopic dermatitis treatment market is growing immensely during the forecast period.

Key Points: 
  • Due to such factors, the atopic dermatitis treatment market is growing immensely during the forecast period.
  • Biological therapies such as anti-interleukin antibodies are widely used for treatment in the atopic dermatitis treatment market.
  • A recent wave of biological products prescribed for treating AD will likely create a lucrative opportunity for growth in the atopic dermatitis treatment market.
  • Despite the plethora of therapies currently available to patients with atopic dermatitis (AD), there is still room for improvement within the treatment space.

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Thursday, December 1, 2022

Patients enrolled in the study will be treated with CTX-471 in combination with KEYTRUDA with the goal of restoring response.

Key Points: 
  • Patients enrolled in the study will be treated with CTX-471 in combination with KEYTRUDA with the goal of restoring response.
  • We are very pleased to be making progress on our CTX-471 clinical program with dosing of the first patient in the combination arm with KEYTRUDA, said Thomas Schuetz, M.D., Ph.D., Chief Executive Officer and Scientific Founder of Compass.
  • CTX-471 has completed a Phase 1 dose escalation and cohort expansion study, where it was shown to be well-tolerated.
  • Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases.

Theralink® Technologies Accepted to Present Two Posters at the Upcoming San Antonio Breast Cancer Symposium

Retrieved on: 
Thursday, December 1, 2022

GOLDEN, Colo., Dec. 1, 2022 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel quantitative protein and phosphoprotein-based assay for breast cancer, today announced the acceptance of two poster presentations evaluating the potential use and utility of its novel RPPA (Reverse Phase Protein Array) technology at the San Antonio Breast Cancer Symposium (SABCS) 2022.

Key Points: 
  • Mick Ruxin M.D., CEO of Theralink Technologies stated, "We are so pleased to have multiple poster presentations accepted at SABCS this year.
  • During our presentations we will highlight the potential of our innovative RPPA-based technology for clinical molecular profiling of breast cancer patients.
  • The Theralink Assay for Advanced Breast Cancer can provide additional levels of quantified clarity for patients who need it the most."
  • The Theralink management team welcomes the opportunity to meet with you in-person in San Antonio at SABCS 2022.

Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

Retrieved on: 
Thursday, December 1, 2022

SAN DIEGO, Dec. 1, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Robert E. Hoffman, President and CEO of Kintara, will be participating at the RHK Capital Disruptive Growth Conference in New York City.

Key Points: 
  • SAN DIEGO, Dec. 1, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Robert E. Hoffman, President and CEO of Kintara, will be participating at the RHK Capital Disruptive Growth Conference in New York City.
  • The RHK Capital Disruptive Growth Conference will feature leading C-suite executives and senior management of up to 30 growth-oriented and disruptive companies to meet with seasoned institutional investors, accredited investors, representatives of family offices, market analysts and financial advisors, as well as broker-dealer wealth managers, and select RHK clients.
  • Kintara's webcast will be held on December 5, 2022 at 2:40 pm ET.
  • To view Kintara's webcast please access the following link:
    Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.

Pyxis Oncology Announces FDA Clearance of Two IND Applications

Retrieved on: 
Thursday, December 1, 2022

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, announced today that it has received clearance for its two Investigational New Drug (IND) applications from the U.S. Food and Drug Administration (FDA) to initiate Phase 1 clinical trials. PYX-201, a novel antibody-drug conjugate (ADC) product candidate, will be investigated for the potential treatment of several solid tumors, including breast, head and neck, lung, and thyroid cancer. PYX-106, an immunotherapy product candidate, will be investigated for the potential treatment of solid tumors, including bladder, cholangio-carcinoma, colorectal, and kidney cancer.

Key Points: 
  • We are thrilled to receive two nearly simultaneous IND clearances from the FDA, representing a major moment as we transition to a clinical stage company demonstrating the operational prowess of our team, said Lara Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology.
  • Jay Feingold, M.D., Ph.D., Chief Medical Officer of Pyxis Oncology, added, "We are excited to advance multiple programs to the clinic.
  • Both product candidates could potentially be applied to a broad range of tumors and address a significant need in the community.
  • Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers.

Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference

Retrieved on: 
Thursday, December 1, 2022

For more information on Kineta, please visit www.kinetabio.com , and follow Kineta on Twitter , LinkedIn and Facebook .

Key Points: 
  • For more information on Kineta, please visit www.kinetabio.com , and follow Kineta on Twitter , LinkedIn and Facebook .
  • KVA12123 (formerly referred to as KVA12.1) is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment.
  • It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope.
  • KVA12123 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian.

Actinic Keratosis Treatment Global Market Report 2022: Future Pipeline Medications and Further Use of Combination Therapy Promise Growth Moving Forward - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022

The global actinic keratosis treatment market size is anticipated to reach USD 8.93 billion by 2030., expanding at a CAGR of 4.1% from 2022 to 2030.

Key Points: 
  • The global actinic keratosis treatment market size is anticipated to reach USD 8.93 billion by 2030., expanding at a CAGR of 4.1% from 2022 to 2030.
  • The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment.
  • Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.
  • In addition, future pipeline medications and the increased use of combination therapy are key market drivers.

Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Retrieved on: 
Wednesday, November 30, 2022

SAN DIEGO, Nov. 30, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the Company has received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) for continued listing on The Nasdaq Capital Market.

Key Points: 
  • SAN DIEGO, Nov. 30, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the Company has received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) for continued listing on The Nasdaq Capital Market.
  • The notice the Company received from Nasdaq on November 29, 2022 noted that the Company evidenced a closing bid price of its shares of common stock at or greater than the $1.00 per share minimum requirement for the last 10 consecutive business days.
  • Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.
  • Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs.The two programs are VAL-083 for glioblastoma (GBM) and REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).

Chiropractic Care in the New Year

Retrieved on: 
Wednesday, November 30, 2022

"This year, I would like more people to resolve to put their health first by prioritizing chiropractic care.

Key Points: 
  • "This year, I would like more people to resolve to put their health first by prioritizing chiropractic care.
  • Dr. Phillips offers a full range of chiropractic services for the new year.
  • Studies show that chiropractic care is effective at treating and managing many health problems.
  • Dr. Phillips Chiropractic Nutrition and Wellness focus on addressing the root causes of illnesses, rather than just treating them with invasive and potentially harmful modalities.

Theralink® Technologies Announces Closing of Private Placement and Conversion of Existing Convertible Notes and Convertible Preferred Shares

Retrieved on: 
Tuesday, November 29, 2022

Additionally, in connection with this offering, holders of certain existing convertible notes and convertible preferred shares of the Company agreed to convert their securities into an aggregate of approximately $13.4 million of the senior secured convertible debentures and warrants on the terms described in the foregoing paragraph.

Key Points: 
  • Additionally, in connection with this offering, holders of certain existing convertible notes and convertible preferred shares of the Company agreed to convert their securities into an aggregate of approximately $13.4 million of the senior secured convertible debentures and warrants on the terms described in the foregoing paragraph.
  • Joseph Gunnar & Co., LLC is acting as the sole placement agent for the offering.
  • Theralink is a proteomics-based, precision medicine company with a CLIA-certified and CAP accredited laboratory located in Golden, Colorado.
  • The Company undertakes no obligation to publicly release statements made to reflect events or circumstances after the date hereof.